Elevated cholesterol and triglyceride levels pose a significant burden on global health. High levels of low-density lipoprotein (LDL) cholesterol and triglycerides are key risk factors for cardiovascular diseases, which are the leading cause of death worldwide. According to the World Health Organization, cardiovascular diseases claim approximately 17.9 million lives annually. A study published in the Journal of the American College of Cardiology reported that high LDL cholesterol alone was responsible for 2.6 million deaths and 29.7 million disability-adjusted life years (DALYs) in 2017. The economic impact is substantial as well, with the American Heart Association estimating costs of $351.2 billion associated with cardiovascular diseases in the United States alone. Investing in research and development to discover innovative interventions and technologies is crucial in addressing this global burden.
World Health Organization (2021) Cardiovascular Diseases (CVDs)
Pre-Clinical results clearly demonstrated that cholesterol and triglyceride levels are significantly reduced after administrating our formulation
Developing a treatment to significantly reduce lipid blood levels with minimal to no significant side-effects
Main active partner & shareholder is Clalit, the 2nd largest HMO in the world and the largest in Israel
The Patent of Cannabidiol and chitosan compositions was granted on 2022 in the US with other territories pending
we are proud to share the impressive results achieved in the multiple pre-clinical trials of our newly developed drug, the CLC, highlighting its remarkable synergy of the APIs and the drug’s efficacy.
Through rigorous testing on various models and studies, our drug demonstrated exceptional performance in terms of lowering dyslipidemia induced elevated lipids through a unique ability to target specific pathways and deliver potent therapeutic effects.
The synergy observed between the drug’s components enhanced its overall efficacy, maximizing its impact on the intended biological targets in comparison to almost no effect of the materials seperatly.
These promising preclinical trial results provide a solid foundation for advancing to the next stage of development, instilling confidence in the potential of our drug to deliver significant clinical benefits.
We are currently in the midst of a phase 2a multicenter double-blind clinical trial aimed at evaluating the effectiveness of our innovative intervention in lowering cholesterol levels.
This trial involves multiple research centers and ensures a rigorous and unbiased evaluation of our treatment approach. The double-blind design helps eliminate any potential biases and ensures reliable and objective results.
Simultaneously, we are actively working towards initiating an additional clinical trial specifically targeting the reduction of elevated triglyceride levels.
By expanding our research efforts, we aim to address the urgent need for effective interventions in managing elevated triglycerides, a significant risk factor for cardiovascular diseases.
These clinical trials reflect our commitment to advancing scientific knowledge and developing innovative solutions to combat the global burden of dyslipidemia.
The company's shareholder and main active partner is mor research applications, the commercializing arm of CLALIT health services, the largest hmo in israel.
This strategic groundbreaking partnership allows us to enjoy:
Under Clalit are:
Approved in the US
The patent of Cannabidiol and chitosan compositions of matter was issued on 2022 in the US, with other major territories pending.
More territories
In addition CannaLean has additional Patents pending for CBD & Chitosan use in all major territories.
CannaLean has a signed right of use on all related chitosan previous patents.
Founder & CEO
Experienced and serial entrepreneur, founded and mentored multiple companies in various fields. Founder of the Talent group including multiple Biotech startup companies in it’s biotech arm. Key investor in over 20 biotech and tech startups.
CFO
Experienced in Public and Private, Multi Millions & Start Ups companies with extensive experience in business & finance. Ofer has vast experience in fundraising from Angel investors & funds.
COO
Experienced and active executive in multiple startup companies, Extensive experience in operations and clinical management in Biotech, Pharma & other technology fields. Graduated B.Sc. in Biology and life science at Tel Aviv University with specialty in biochemistry.
Vast medical experience with an international reputation. Served as Chairman, Department of Medicine and a Hematology Consultant at the Tel Aviv Sourasky (Ichilov) Medical Center. Proficient and experienced with multiple medical and health technologies and fields.
Vast experience as CSO, CTO and other key scientific positions in many biotech companies and startups. Director at Mor Research Applications.
Head of Foot and Ankle Department and Orthopedic Research Unit at HaSharon Hospital. Chairman of the Israeli Cannabis association. Specialist in Medical Cannabis for pain. Serial inventor and Medical Director at various orthopedics companies including Cartiheal.
